Phase II clinical trial of combination of personalized peptide vaccination with low dose Cyclophosphamide for advanced sarcoma patients
- Conditions
- sarcoma
- Registration Number
- JPRN-UMIN000012696
- Lead Sponsor
- Kurume University Cancer Vaccine Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
The following patients must be excluded. 1)Patients with sereve symptoms(active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disease of coagulation and so on.) 2)Patients with the past history of severe allergic reactions. 3)(Females) Patients who are during pregnancy, lactation expectant and desiring future fertility. (Males) Patients do not accept contraception during the 1st vaccination to 70 days after last vaccination. 4)Patient who have active double cancer(synchronous double cancer and metachronous double cancer within 5 disease-free years),excluding carcinoma in situ(lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 5)Patients who are judged inappropriate for the clinical trial by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method